| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
|
| | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide Basic information |
| Product Name: | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide | | Synonyms: | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide;Pyrimidine Related Compound 1;ap261133;Benzenesulfonamide, 2-chloro-N,N-diethyl-5-[[4-[2-[4-[[(methylamino)carbonyl]amino]phenyl]-4-pyridinyl]-2-pyrimidinyl]amino]-;hSMG-1 inhibitor 11j;hSMG 1 inhibitor 11j,hSMG1 inhibitor 11j;2-Chloro-N,N-diethyl-5-((4-(2-(4-(3-methylureido)phenyl)pyridin-4-yl)pyrimidin-2-yl)amino)benzenesulfonamide;SMG1i | | CAS: | 1402452-15-6 | | MF: | C27H28ClN7O3S | | MW: | 566.07 | | EINECS: | | | Product Categories: | Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds | | Mol File: | 1402452-15-6.mol | ![2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide Structure](CAS/20150408/GIF/1402452-15-6.gif) |
| | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide Chemical Properties |
| density | 1.353±0.06 g/cm3(Predicted) | | storage temp. | 4°C, away from moisture and light | | solubility | DMSO: 2mg/mL, clear | | form | Solid | | pka | 14.00±0.46(Predicted) | | color | White to yellow |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide Usage And Synthesis |
| Uses | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(methylamino)carbonyl]amino]phenyl]-4-pyridinyl]-2-pyrimidinyl]amino]benzenesulfonamide are pyrimidine derivatives as hSMG-1 inhibitors. | | Biological Activity | Potent and selective SMG-1 (hSMG-1; SMG1) kinase inhibitor th at blocks nonsense-mediated decay (NMD).
SMG1i is a potent and selective SMG-1 kinase inhibitor (hSMG-1 IC50 = 110 pM) with much reduced potency against mTOR, PI3Kα/γ and CDK1/2 (IC50 = 50 nM, 92/60 nM, 32/7.1 μM, respectively). SMG1i selectively downregulates MDA361 cellular phosphorylation of UPF1 (0.3 -1 μM), but not th at of mTOR or AKT substrates (p70s6 K and PI3K). Nonsense-mediated decay (NMD) inhibition by SMG1i (1 μM) is shown to synergize with premature termination codons (PTCs) readthrough agents (G418, gentamicin, and paromomycin) in promoting the expression of CFTR protein in murine cells carrying Cftr G542X nonsense mutation. | | IC 50 | hSMG-1: 0.11 nM (IC50); mTOR: 50 nM (IC50); PI3Kγ: 60 nM (IC50); PI3Kα: 92 nM (IC50); GSKα: 260 (IC50); GSKβ: 330 (IC50); CDK2: 7.1 μM (IC50); CDK1: 32 μM (IC50) |
| | 2-Chloro-N,N-diethyl-5-[[4-[2-[4-[[(MethylaMino)carbonyl]aMino]phenyl]-4-pyridinyl]-2-pyriMidinyl]aMino]benzenesulfonaMide Preparation Products And Raw materials |
|